Q4 2025 Dimed SA Distribuidora de Medicamentos Earnings Call Transcript
Key Points
- Dimed SA Distribuidora de Medicamentos (BSP:PNVL3) achieved a 17% sales growth in 2025, demonstrating strong performance in a challenging market.
- The company reported a significant increase in digital sales, reaching 54% in the fourth quarter, contributing to a 28.5% sales share.
- Panvel products, a key growth driver, represented nearly 20% of hygiene and beauty sales, highlighting the strength of their own brand.
- The company maintained a strong market share in the South of Brazil, reaching nearly 14%, indicating successful regional consolidation.
- Dimed SA Distribuidora de Medicamentos (BSP:PNVL3) achieved a record high EBITDA of nearly BRL105 million in Q4 2025, reflecting a 28% growth compared to the previous quarter.
- The company faces ongoing supply restrictions with GLP-1 products, particularly Mounjaro, which could impact future sales.
- There is pressure on gross margins due to the competitive market and the growth of GLP-1s, which could affect profitability.
- The potential reduction in working hours in Brazil could lead to decreased productivity and increased operational challenges.
- The company is exposed to risks associated with the large counterfeit market for GLP-1s, which is three times the size of the formal market.
- Dimed SA Distribuidora de Medicamentos (BSP:PNVL3) must navigate the complexities of transitioning from wholesale to a purely retail-focused operation, which may present challenges in maintaining growth momentum.
Good morning, ladies and gentlemen. And welcome to Grupo Panvel's conference call where we will discuss the results for the fourth quarter of 2025. This conference call is being recorded, and you may watch it on the company's investor relations website. The company's presentation is also available for download there. We'd like to inform you that all participants will be in listen-only mode during the company's presentation, and after that we will begin the questions-and-answer session when further instructions will be given. We have translations into English and Brazilian sign language. You can access them through the interpretation button.
Before we continue, I'd like to underscore that statements about the future are based on the company's beliefs and assumptions and on the information that is currently available for the company. These statements may involve risks and uncertainties as they refer to future events and therefore depend on circumstances that may or may not occur. Investors, analysts, and journalists should take into account that any conditions in the macroeconomic scenario, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
